Which drugs are closest competitors to Farxiga (dapagliflozin)?
Farxiga (dapagliflozin) is a type of medicine called an SGLT2 inhibitor. Its main competitive set includes other SGLT2 inhibitors used for similar conditions such as type 2 diabetes (glycemic control) and, in many markets, heart failure and chronic kidney disease indications. Common competitors in this class are:
- Jardiance (empagliflozin)
- Invokana (canagliflozin)
- Steglatro (ertugliflozin)
Because SGLT2 inhibitors share a similar mechanism (blocking glucose reabsorption in the kidney), they often compete directly where multiple agents are eligible for the same patient populations and outcomes.
Farxiga vs Jardiance: how do they compete in practice?
Jardiance (empagliflozin) is typically viewed as one of Farxiga’s closest rivals. Both target the same general SGLT2 inhibitor mechanism and are marketed across overlapping therapeutic areas (especially type 2 diabetes, and also heart and kidney indications depending on local approvals and prescribing practices). In formularies and treatment pathways, differences that can drive selection often come down to:
- specific approved indications in a given country
- dosing convenience and labeling
- payer/formulary placement and contracting
- clinical fit for the patient (comorbidities, kidney function thresholds, and safety considerations)
Are non-SGLT2 drugs also competitors?
Yes. Even if they are not in the same drug class, other diabetes and cardio-renal medicines can compete when prescribers are choosing a therapy plan for the same patient goals, such as:
- lowering blood glucose in type 2 diabetes
- reducing cardiovascular risk or heart-failure events
- slowing progression of chronic kidney disease
That means Farxiga can face competition not only from other SGLT2 inhibitors, but also from other drug classes used for diabetes and cardio-renal risk reduction, depending on what the patient needs and which options are preferred by guidelines and payers.
What about the biggest competitive pressure: class members vs “placeholders”?
Within the SGLT2 inhibitor space, direct competition is usually the most intense against other SGLT2 inhibitors (Jardiance, Invokana, Steglatro) because they can be substituted at the same stage of therapy for many patients. Outside the class, competition tends to depend on:
- which outcomes are being targeted (glycemic control vs cardio-renal outcomes)
- patient-specific contraindications and tolerability
- local coverage and step-therapy rules
Where can I check Farxiga patent/exclusivity and competitor landscape?
For patent and exclusivity-related timing that can affect market competition, DrugPatentWatch.com tracks drug-specific IP and related developments. You can search Farxiga there for updates that may influence competitor entries and launch timing:
- https://www.drugpatentwatch.com/ (search for “Farxiga”)
Sources
- https://www.drugpatentwatch.com/